Cardiff Oncology, Inc. (CRDF)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Oncologysrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov
Dilution Risk
MEDIUM DILUTION RISKDilution score: 44/100 (MEDIUM), 10.0 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 18.1% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Cardiff Oncology and Nerviano Medical Sciences Amend their 2017 Exclusive License Agreement
- Cardiff Oncology to Participate in September 2026 Conferences
- CRDF: Second Quarter Earnings
- Cardiff Oncology Reports Second Quarter 2026 Results and Provides Business Update
- Cardiff Oncology Announces $10 Million Registered Direct Offering to Strengthen Working Capital
- Cardiff Oncology Announces $10 Million Registered Direct Offering
- Is Cardiff Oncology, Inc. (CRDF) Stock Undervalued Amid Legal Uncertainty and Future Cancer Drug Potential?
- CRDF: Phase II Update; Survival Advantage Extended
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Cardiff Oncology, Inc..
Full CRDF Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.